Summary

The product HCG, manufactured by Lemon@arailpharma.me and submitted by Arail Pharmaceuticals, underwent independent testing to verify its composition. The sample, identified as batch number 1, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The test confirmed that the vial contained 16,186 IU of Human Chorionic Gonadotropin (HCG) as measured by immunoassay.

The testing process began on 5 November 2024, with the sample received on 15 November 2024, and analysis completed on 18 November 2024.


Detailed Report

Product Overview

Testing Details

Testing Results


Verification Details


Evaluation of Manufacturer-Submitted Testing

The test confirms that the HCG sample contains 16,186 IU, as expected for a peptide vial. While this is a positive indicator of product authenticity, it remains a single-batch test submitted by a manufacturer. For a more comprehensive assessment, multiple batch tests and independent third-party verification are recommended.


Conclusion

The test confirms that the HCG product contains the expected Human Chorionic Gonadotropin with an immunoassay-confirmed concentration of 16,186 IU. However, further independent testing across multiple batches is advised to ensure consistency and reliability.


Disclaimer

This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may have inherent biases, but it still provides valuable insights when cross-checked with independent analysis. Readers should interpret this information critically and responsibly.